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In the last decade, a global trend of escalating ecstasy (MDMA, MDA,
MDEA, MBDB) use was observed. Mentions on medical death certiﬁcates,
last year’s ecstasy use, number of drug offenders, seizures, prices and
dosage-levels ﬁgures were used for this descriptive and correlational
study. Figures (1994–2003) were taken from the UK General Mortality
Registers, from the Home Ofﬁce Statistical Bulletins, from the British
Crime Survey and from those reported to both the National Crime
Intelligence and Forensic Science Services. A total of 394 ecstasy deaths
mentions were here identiﬁed from the UK; in 42% of cases ecstasy was
the sole drug mentioned. Overall, number of fatalities showed a year-per-
year increase and positively correlated with: prevalence of last year’s use
(p0.01); number of offenders (p0.01) and number of seizures
(p0.01) but negatively correlated with ecstasy price (p0.05). Price
negatively correlated with: prevalence of last year’s use (p0.001) and
number of seizures (p0.01); but positively correlated with average
MDMA dosage per tablet (p0.01). MDA, MDEA and MBDB accounted for
a signiﬁcant proportion of tablets only up to 1997, but not afterwards.
Increasing production with a concomitant decrease in ecstasy price may
have facilitated an increase in consumption levels and this, in turn, may
have determined an increase in number of ecstasy deaths mentions. Only
medical death certiﬁcates and not coroners’ reports at the end of their
inquests were here analysed; no data were available in respect of other
drugs use and toxicology results.
Keywords
MDMA, ecstasy deaths, ecstasy seizures, ecstasy prevalence of use,
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Introduction
In the second part of the 1990s, a global trend of escalating
ecstasy use was observed. Although mostly identified with 3,4-
methylenedioxymethamphetamine (MDMA), tablets containing
3,4-methylenedioxyamphetamine (MDA), 3,4-methylene-
dioxyethylamphetamine (MDEA) and 2-methylamino-1-(3-4-
methylenedioxyphenyl)butane (MBDB) have been frequently
referred to as ‘ecstasy’ as well (Schifano, 2001). Anecdotal reports
have suggested that the use of ecstasy is an issue of concern across
a number of different countries. Yacoubian (2003), in collecting
data from three different sources to explore ecstasy use trends in
the USA during the 1990s, confirmed that use of ecstasy has
increased over time. According to Landry (2002), exposure to
MDMA among high school seniors in the USA has increased pro-
gressively and nearly quadrupled over the past decade. Both
researchers were of the opinion that availability of MDMA and
quantity seized by US law enforcement has increased dramatically
during the 1990s, as have the number of MDMA-related arrests.
Between 1995 and 1998, the lifetime prevalence of ecstasy use
doubled to 5% of Australia’s general population. Increase in the
number of people using ecstasy, decline in the age of initiation,
and growing popularity of ecstasy use among ‘mainstream’ people
who do not fit the stereotype of an illicit drug user have all been
described (Topp et al., 2004). Wilkins et al. (2003) examined
changes in the use of ecstasy in New Zealand. Last year use of
ecstasy increased from 1.5% in 1998 to 3.4% in 2001. In 2001,
43% of users thought ecstasy was easier to obtain and 29%
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thought the price was lower compared with a year earlier. In
Turkey, Corapcioglu and Ogel (2004) reported that while the per-
centage of those who used ecstasy at least once in their lifetime
was 2.65% in 1998, the figure reached 3.31% in 2001.
Prevalence of recreational ecstasy use in Europe is not clearly
defined; national surveys report lifetime prevalence of ecstasy use
among males aged 15–24 years of 11–17% in the Czech Republic,
Spain, the Netherlands and the United Kingdom, and recent use
rates of 5–13% in the Czech Republic, Spain, Ireland, Latvia, the
Netherlands and the United Kingdom. It is likely that these figures
would be even higher if only urban populations were considered
(EMCDDA, 2004).
Over the last 5 years, among EU Member States, the United
Kingdom has consistently been the country to seize most ecstasy
(EMCDDA, 2004). Aust, Sharp & Goulden (2002) provided a
‘best’ estimate of regular UK ecstasy users, which should be about
730000 (680000 in England and Wales; 30000 in Scotland and
20000 in Northern Ireland). Bramley-Harker (2001) calculated
that the UK demand for ecstasy in 1998 was 26786000 tablets,
although this was recognized to be probably an under-estimate.
The ratio of occasional to regular users was 5:1. Self-selected
respondents to postal surveys suggested that on average three to
four tablets are consumed in a normal ‘session’ (Craske, 2002).
Dividing Bramley-Harker’s demand figure by four would suggest
about 6.7 million ecstasy ‘sessions’ a year.
Most ecstasy consumption takes place at clubs, raves and other
such venues (EMCDDA, 2004; Schifano, 2000). Clubbers’
surveys show both more frequent use and elevated rates of con-
sumption compared to the general population (Measham et al.,
2001). Bellis et al. (2003) reported that proportions of Britons
using ecstasy, cocaine and GHB whilst on holidays abroad have
risen significantly between 1999 and 2002, as have numbers of
ecstasy tablets taken on a usual night.
Although use trends are increasing, data regarding the hazards
of MDMA are limited. Patel et al. (2004) obtained fatality reports
from participating medical examiners in the United States. Thirty-
eight (8%) of the surveyed medical examiners reported 102 deaths
associated with MDMA use from 1999 to 2001. Ten per cent of
fatalities occurred in 1999 and 90% thereafter, representing a
400% relative increase. The risk of ‘overdose’ with ecstasy has
been described in the UK since the early 1990s (Henry et al.,
1992). In England and Wales, a steady and constant increase of
ecstasy (MDMA, MDA, MDEA)-related fatalities has been
observed in the time frame August 1996–April 2002, when a total
of 202 related deaths were recorded (Schifano et al., 2003a). A
consistent decrease in the purchase costs of ecstasy tablets had
been hypothesized, but not demonstrated, to be one of the signific-
ant factors for this increase in fatalities (Schifano, 2004).
Sumnall et al. (2004) investigated the influence of price upon
hypothetical purchases of alcohol, amphetamine, cocaine and
ecstasy for 43 current polysubstance misusers. Increasing the price
of ecstasy significantly reduced the number of purchases. They
found that purchases decreased at rates proportionally greater than
the increases in prices. In assuming that drug use patterns follow
the simulated purchases in their experiment, Sumnall et al. (2004)
suggested that polysubstance misusers might alter their drug using
behaviour based on the purchase price of the drugs available to
them.
Six key indicator data sources (i.e. number of mentions on
death certificates, last year’s use, number of drug offenders,
seizures, price, average MDMA dosage levels per tablet) were
here deemed appropriate for contribution to a descriptive overview
of ecstasy trends, which was the main aim of this study. Further-
more, we aimed at testing the hypothesis that these indicators were
inter-related to each other. We hypothesized that ecstasy price
fluctuations over the years inversely correlated with levels of
ecstasy availability and numbers of ecstasy deaths.
Methods
This descriptive and correlational study covered the period
January 1994 to December 2003. There are two main types of
source in the UK for regular information on ‘acute’ drug-related
deaths (DRDs): three General Mortality Registers (GMRs) and
one Special Mortality Register (the National Programme of Sub-
stance Abuse Deaths (npSAD); Ghodse et al., 2004). The GMRs
are the General Register Offices for England and Wales, Scotland,
and Northern Ireland. Essentially, the mortality data recorded by
these offices are derived from medical death certificates. No
detailed information is passed to them on toxicology, e.g. levels of
drugs and/or alcohol found in body tissues, blood or urine. Post-
mortem reports are not provided to the GMRs. Death figures were
here obtained from the Office of National Statistics (ONS, includ-
ing the General Register Office for England and Wales; Christo-
phersen et al., 1998), from the General Register Office for
Scotland (GROS; Jackson, 2004) and from the Department of
Health, Social Services and Personal Safety for Northern Ireland,
which has direct access to the data files at the General Register
Office for Northern Ireland (GRONI). Figures given here were
total mentions of ecstasy (i.e. MDMA, MDA, MDEA, MBDB) on
medical death certificates for fatalities occurring in the years
1994–2003; separate figures for the four different molecules were
not provided to us. Before 1994, these figures were not available
for all parts of the UK. The total figures for each constituent
country were added together to obtain UK figures. Different from
here, previous UK ecstasy-related fatalities studies (Schifano et
al., 2003a; Schifano et al., 2003b) analysed figures collected
taking into account the npSAD (Ghodse et al., 2004) definition of
ecstasy (MDMA, MDA, MDEA)-related deaths, with coroners’
reports at the end of their inquests, and not death certificates,
being analysed. Drug-related deaths using the standard definition
employed by the Office of National Statistics (Griffiths, 2004)
were as follows: ICD-10 codes F11–F16, F18, F19, X40–X44,
X60–64, X85 and Y10–Y14. The number of persons dealt with for
drug offences involving ecstasy; the number of seizures of ecstasy
and the number of doses of ecstasy seized in the UK were taken
from the Home Office Statistical Bulletins (Corkery, 2002; Ahmad
and Mwenda, 2004). Data on number of seizures and number of
doses seized were made available only for the period 1994–2002.
Data on both average MDMA dosage levels per tablet and ecstasy
content in terms of MDMA, MDA, MDEA, MBDB were based
2 UK ecstasy ﬁgures, 1994–2003
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upon analyses carried out for the 1994–2001 period by the Foren-
sic Science Service in part of the material seized by the UK police
(Forensic Science Service, 2003). Information on last year use of
ecstasy recorded by the British Crime Survey (BCS) was taken
from the appropriate Home Office publications (Ramsay et al.,
2001; Aust et al., 2002). The drug misuse self-completion compo-
nent of the British Crime Survey asks about drug use (i.e. cocaine,
crack, ecstasy, heroin, LSD, magic mushrooms and methadone)
over the respondent’s lifetime, in the last year and in the last
month; the indicator presented here referred to respondents’ use of
ecstasy in the last year. Figures related to general household
surveys conducted in England and Wales only and were the results
for respondents age 16–29 for the sweeps in 1994, 1996, 1998 and
2000 and of 16–24 year olds in 2000/1 and 2002/3 (the age groups
changed for the last two sweeps). The figures for intermediate
years e.g. 1995 were the mid-point between the rates for the year
preceding and year following e.g. 1994 and 1996. Prices were
given in pounds sterling without any adjustment for inflation.
They related to average UK street-level prices per tablet/dose of
ecstasy as reported by police forces to the National Crime Intelli-
gence Service (NCIS, 2002; Bellis et al., 2004) for the period
1994–2003. They were based on police officers asking dealers
how much they charged and in some areas from test purchases.
To identify possible correlations between the different indic-
ators, the Pearson coefficients were calculated.
Results
The total number of deaths where ecstasy (MDMA, MDA,
MDEA, MBDB) was mentioned in the UK rose from 31 in 1994
to 78 in 2002, but dropped to 48 in 2003. Over the years, ecstasy
was involved in a total of 394 deaths and was the sole drug men-
tioned in 165 (41.9%) occasions. In the remaining cases, ecstasy
was mentioned together with other drugs and/or with alcohol.
According to the UK BCS results, ecstasy last year use rose from
3% in 1994 to its peak (6.8%) in 2001, before falling back to 5.4%
in 2002–2003. In 2001, some 7370 individuals were cautioned by
the police or dealt with by the courts for drug offences involving
ecstasy-type drugs. This was a fourfold increase on the 1994
figure of 1881. The number of occasions on which ecstasy was
seized within the UK by law enforcement agencies rose threefold
(from 3614 to 10460) between 1994 and 2001. During the same
period, the quantity of ecstasy (in terms of doses/tablets) seized
rose fivefold (from 1598200 to 8030000). The price of ecstasy in
the UK has fallen rapidly over the past decade. In 1994, the
average price of a dose/tablet was £16.50, but by 2003 this figure
had reduced by almost 70% to £5.30. If the effects of inflation are
taken into account, the fall in real terms is even greater. The
average MDMA dosage levels per tablet showed a decrease over
the years, being about 100mg by 1994–1995 and reducing to
74mg by 2000–2001.
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Figure 1 UK ecstasy trends, 1994–2003
Death mentions: provided by ONS, GROS and GRONI. BCS refers to respondents’ ecstasy use in the last year; England and Wales only. The number of
persons dealt with for drug offences involving ecstasy-type drugs; the number of seizures of ecstasy-type drugs and the number of doses of ecstasy-
type drugs seized in the UK were taken from the Home Ofﬁce Statistical Bulletins. Ecstasy prices are given in £ sterling. Data on seizures were not
made available for 2003. Data on average MDMA dosage levels per tablet were those reported by the Forensic Science Service and were not made
available for 2002–2003.
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With respect to variation of ecstasy tablets’ content in terms of
MDMA, MDA, MDEA and MBDB, it appeared that MDMA
accounted for no more than 50–75% of ecstasy tablets in
1994–1997 but, after 1998, it was identified as the active ingredi-
ent in 97–100% of tablets. Before 1998, MDEA accounted for up
to 45% of tablets whilst MDA and MDEA were respectively
found in a range of 1–8% and 0–7% of the so-called ecstasy
tablets.
Time series for ecstasy (MDMA) have been plotted against the
following key indicators: number of death mentions, prevalence
(England and Wales only; last year use from the British Crime
Survey), number of persons found guilty or cautioned, number of
seizures (UK), number of doses seized, price and average MDMA
dosage levels per tablet as in Fig. 1. As can be seen from Table 1,
Pearson correlation coefficients calculated were all significant. In
particular, number of death mentions positively correlated with:
prevalence of last year’s use (p0.01); number of offenders
(p0.01); number of seizures (p0.01) and number of doses
seized (p0.05) but negatively correlated with ecstasy price
(p0.05) over the years. Ecstasy price negatively correlated with:
prevalence of last year’s use (p0.001); number of offenders
(p0.001); number of seizures (p0.01) and number of doses
seized (p0.05) but positively correlated with average MDMA
dosage level per tablet (p0.01).
Discussion
This report has provided a 10-year, UK-wide, ecstasy (MDMA,
MDA, MDEA, MBDB) official figures data set. The findings of
this study have confirmed the increase in ecstasy availability, con-
sumption, offenders and deaths figures for the UK over the period
1994–2003 and have highlighted how these figures were nega-
tively correlated with ecstasy price fluctuations over the years. On
the other hand, over the period 1994–2001, ecstasy prices posi-
tively correlated with MDMA average dosage levels per tablet.
Furthermore, results have shown that although in the mid-1990s
MDEA, MDA and MBDB accounted for a significant proportion
of tablets, since 1998, MDMA was identified as the only active
compound in ecstasy tablets.
With respect to ecstasy deaths mentions, the UK results shown
here are consistent with previous (1997–2000, Schifano et al.,
2003a; August 1996–April 2002, Schifano et al., 2003b) findings
from England and Wales. Ecstasy accounted for 1.2% of all UK
DRD deaths in 1997, but by 2001 and 2002 this proportion had
risen to 4.1% (Bellis et al., 2004; EMCDDA, 2004). On the other
hand, the 2003 drop in ecstasy deaths mentions here reported is
consistent with most recent EMCDDA (EMCDDA, 2004) and
npSAD (Ghodse et al., 2004) findings.
There may be a few possible explanations, not necessarily con-
tradicting each other, for the overall increase in number of ecstasy
deaths mentions here observed. These include: larger availability
of ecstasy in the UK with respect to most of the other European
Union countries (EMCDDA, 2004); increase in ecstasy consump-
tion in a polysubstance misuse context (Schifano, 2004); higher
reporting rate, on the coroners’ side, of ecstasy. A huge media
interest surrounded some of the high profile cases of ecstasy-
related fatalities occurring in the mid-1990s in the UK and this
may have increased awareness of drug intake possible con-
sequences. In turn, this may have led to improved surveillance,
monitoring and recording of the substance in investigations of
sudden deaths of young people.
Previous analysis of npSAD ecstasy mortality data from
England and Wales had suggested that ecstasy was the sole drug
4 UK ecstasy ﬁgures, 1994–2003
Table 1 Variation of ‘ecstasy’ tablets’ content in terms of MDMA, MDA, MDEA and MBDB (UK; 1994–2003)
Years MDMA % MDA % MDEA % MBDB % Total
Number of 

Number of 

Number of 

Number of 
ecstasy seizures ecstasy seizures ecstasy seizures ecstasy seizures 
reported to the reported to the reported to the reported to the 
Forensic Science Forensic Science Forensic Science Forensic Science 
Service Service Service Service
1994 1966 75.1 132 5 520 19.9 0 0 2618
1995 1835 52.4 282 8.1 1384 39.5 0 0 3501
1996 530 47.3 36 3.2 501 44.7 53 4.7 1120
1997 763 74.4 9 0.9 183 17.9 70 6.8 1025
1998 1329 97.3 5 0.4 29 2.1 3 0.2 1366
1999 2528 98.1 17 0.7 28 1.1 3 0.1 2576
2000 5101 96.5 39 0.7 144 2.7 2 0.0 5286
2001 6294 98.6 33 0.5 59 0.9 0 0 6386
2002 5808 99.6 11 0.2 10 0.2 0 0 5829
2003 6300 98.8 18 0.3 57 0.9 0 0 6375
(Data were taken from analyses of ecstasy seizures reported by the UK Police to the Forensic Science Service).
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implicated in death in 7% (Schifano et al., 2003a) to 17% (Schi-
fano et al., 2003b) of cases reported by coroners. According to the
present figures from the UK General Mortality Registers (GMRs),
ecstasy was the sole drug mentioned in the death certificate in
42% of the total number of related fatalities. The reason for the
discrepancy in the data between the npSAD and the GMRs may be
due to the fact that the npSAD data capture system allows collec-
tion of fairly detailed information from coroners. As a con-
sequence, a more precise description of the index ecstasy-related
death is made possible and this may have decreased, in the npSAD
mortality studies, the number of cases in which the compound was
considered to be involved on its own.
Increase in ecstasy deaths mentions figures was positively cor-
related with levels of ecstasy availability indicators. Conversely,
ecstasy price negatively correlated both with availability indic-
ators, thus confirming the Sumnall et al. (2004) laboratory find-
ings and death figures. This seems to provide some support to the
most simple of the hypotheses, i.e. that the massive decrease in
ecstasy price here observed over the years has facilitated an easier
access to the drug and hence an increase in its consumption levels.
This, in turn, has determined an increase in number of related
fatalities. Increase in ecstasy consumption may cause a rise in
number of deaths in at least two different ways. At the individual
level, some consumers may binge with larger numbers of pills and
this may be the cause of serious concern. Interestingly, ecstasy
price decreased over the years in parallel with average MDMA
dosage per tablet. The decrease in MDMA content per single
tablet can determine an increase in number of tablets ingested.
However, a small increase in MDMA dosage can lead to a dispro-
portionate rise in drug plasma concentration (‘non linear’ pharma-
cokinetics; de la Torre et al., 2000). At the population level, on the
other hand, an increase in consumption may well mean an increase
in the number of individuals experimenting with ecstasy. In this
way, it will be more likely that the minority of individuals which
are hypothetically at higher risk of ecstasy acute medical sequelae
will be approaching the compound. After acute ecstasy adminis-
tration, a number of different physical complications have been
reported: tachycardia, asystolia, arrhythmias, hypertension, meta-
bolic acidosis, cerebral haemorrhages, convulsions, coma, rhab-
domiolysis, mydriasis, vomiting, diarrhoea, thrombocytopoenia,
disseminated intravascular coagulation, acute kidney failure
(Landry, 2002; Sanjurjo et al., 2004; Schifano, 2004). The sympa-
thomimetic stimulation may be exacerbated by the environmental
condition (Parrott, 2001). Adverse effects of MDMA may be
related to metabolism, which is regulated by the levels of the
hepatic enzyme CYP2D6. About 5–9% of Caucasians are deficient
in this enzyme (Tucker et al., 1994), so that poor metabolizers
may be at greater risk of toxic responses to the drug even at low
doses (Ramamoorthy et al., 2002) but no data have confirmed
these expectations so far (Gilhooly and Daly, 2002). The COMT
enzyme is involved in the transformation of 3,4-dihydroxy-
methamphetamine-HHMA (the main MDMA metabolite) to 4-
hydroxy-3-methoxymethamphetamine-HMMA (Helmlin et al.,
1996; Segura et al., 2001). Approximately 25% of the Caucasian
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Table 2 Pearson correlation coefﬁcients for the UK ‘ecstasy’ indicators, 1994–2003
Death Last year’s use Number of Number of Number of Prices Average 
mentions prevalence offenders seizures seized MDMA 
(England and tablets/doses content per 
Wales only) tablet (mg)
Death mentions Pearson 1
Sig.
Last year’s use prevalence 
(England and Wales only) Pearson 0.854** 1
Sig. 0.002
Number of offenders Pearson 0.815** 0.930** 1
Sig. 0.004 0.000
Number of seizures Pearson 0.805** 0.917** 0.970** 1
Sig. 0.009 0.001 0.000
Number of seized tablets/doses Pearson 0.749* 0.825** 0.787* 0.853* 1
Sig. 0.02 0.006 0.012 0.003
Prices Pearson 0.710* 0.862** 0.872** 0.825** 0.711* 1
Sig. 0.021 0.001 0.001 0.006 0.032
Average MDMA content Pearson 0.454 0.689 0.672 0.595 0.564 0.878** 1
per tablet (mg) 0.259 0.059 0.068 0.120 0.146 0.004
***Correlation is signiﬁcant at the 0.001 level (2-tailed)
**Correlation is signiﬁcant at the 0.01 level (2-tailed)
*Correlation is signiﬁcant at the 0.05 level (2-tailed)
(Calculations related to seizures and MDMA average content per tablet referring respectively to 1994–2002 and 1994–2001 data only)
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population present low COMT activity (Zhu, 2002). HMMA may
stimulate the release of the anti-diuretic hormone vasopressin so that
excessive water retention, coupled with hyponatraemia, can be
observed (Fallon et al., 2002; Forsling et al., 2002). Young women
may be at greater risk (Parr et al., 1997; Budisavljevic et al., 2003).
One could conclude that range of COMT activity (due to genetic
polymorphism) may explain some of the inter-individual differences
in vasopressin secretion after MDMA consumption.
Understandably, the amount of MDMA per tablet and the pro-
portion of ecstasy tablets containing MDMA are central to any
discussion of ecstasy acute detrimental effects. Data shown here
are in general agreement with previous reports from the UK. Cole
et al. (2002) analysed all tablets submitted to the Forensic Science
Service in the north-west of England during 2001. All tablets sub-
mitted were found to include MDMA, whilst others contained
MDEA as well and their content ranged from 20–109mg with the
mean being in the 60–69mg range. Parrott (2004) found that,
during the mid-1990s, the majority of ecstasy tablets contained
MDMA while many others comprised MDA or MDEA. However,
a small proportion comprised non-amphetamine drugs such as caf-
feine, ephedrine, ketamine, paracetamol or placebo. He suggested
that, during the late 1990s, the proportion of ecstasy tablets con-
taining MDMA increased to around 80–90% with non-MDMA
tablets lately being very infrequent and characterized by purity
levels between 90% and 100% (Parrott, 2004).
There are limitations with the information collected and pub-
lished by the UK GMRs, such as the ONS, GROS and GRONI.
The number of cases identified here were actually ‘mentions’ of
ecstasy on death certificates, i.e. no information was available in
respect to ecstasy and concomitant other drugs’ dosage, post
mortem reports, toxicology results and setting characteristics.
Ecstasy inclusion on those documents submitted to GMRs did not
necessarily mean that this drug directly ‘caused’ the death, but that
ecstasy (MDMA, MDA, MDEA, MBDB) was found at post-
mortem and/or was identified by toxicological screening. A
number of methodological problems can contribute to make it dif-
ficult to interpret the role ecstasy plays in the so-called ‘ecstasy-
related’ deaths and especially so if accurate information is not
available. Polydrug abuse ingestion itself may act as a confound-
ing factor; the suggested ecstasy/polydrug occasional user model
is characterized by at least three different psychoactive com-
pounds taken on the same occasion (Schifano, 2004). Co-
occurrence of two stimulants (i.e. MDMA together with
amphetamine and/or cocaine) might increase, in a synergic way,
both the dopaminergic and serotonergic stimulation, so that the
serotonin syndrome (Parrott, 2002) may be more likely to occur.
Moreover, the mixed use of hallucinogens (i.e. ketamine and/or
LSD together with MDMA) might increase the occurrence of
intoxicated ‘behaviours’, such as dangerous driving, with a conse-
quent higher risk of a fatal outcome (Schifano, 2004). Conversely,
concurrent use of sedatives could somewhat mitigate the excess of
sympathomimetic overactivity (Hunt, 2003). On the other hand,
when ecstasy was mentioned on its own, one could assume that
the substance recorded may have been more directly implicated in
the fatality (Schifano et al., 2003a; Schifano et al., 2003b; Schi-
fano, 2004).
A possible limitation of these data is given by reporting
biases over time. In the first part of the 1990s, ecstasy may not
have been screened for systematically. As a consequence, earlier
years’ figures shown here might be lower than real figures.
Moreover, number of offenders and number of seizures may
reflect changes in policies, priorities and activities of law
enforcement agencies. The quantities of drugs seized over time
may reflect both variations in intelligence-led activities of law
enforcement agencies and a fluctuating availability of drugs on
the black market.
One could argue that correlations between some of the vari-
ables were very high. In particular, there was a strong correlation
between number of seizures and number of offenders. Although
this may suggest that there may be some confounding variable
underlying all the data, the nature of the relationships between the
different variables is not straightforward and may change over
time.
Although reports on ecstasy prices from the National Crime
Intelligence Service are the best available from the UK, these data
have their own limitations. Average prices are calculated from
information submitted by individual officers from different police
force areas, and at varying periods, on a non-systematic and non-
stratified basis. Most information is probably anecdotal in nature
and is not based on routine ‘test purchases’, although this is some-
times done by the Metropolitan Police.
Above limitations need to be borne in mind when looking at
trends over time, but systematic monitoring of trends in illicit drug
markets is imperative to provide the basis for effective practice in
the health and law enforcement sectors (Topp et al., 2004). In
particular, there is a need for routine/regular collection and analy-
sis of detailed information on deaths associated with ecstasy.
Further research should better describe the clinical implications of
ecstasy misuse in the context of polydrug intoxication and should
also specifically address the issue of possible individual psychobi-
ological/genetic vulnerability to ecstasy deaths.
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